transcribed from fax received on 06/16/21pdf – http://vpwas.com/skm_c224e21062210410/ Date: June 15, 2021Bristol Myers Squibb would like to inform you that the sale and distribution of Sustiva® (efavrinz) will be discontinued in Canada. Sustiva® (efavrinz)is indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents. This discontinuation includes tablet (600mg) formulation on September 30, 2022 and capsule (50mg and 200mg) formulation on March 31, 2023. The decision to discontinue Sustiva is voluntary and not related to any quality, […]
Read more →